Phase I study of cisplatin, gemcitabine and lapatinib as first line treatment in advanced/metastatic urothelial cancer.
Latest Information Update: 10 Nov 2021
At a glance
- Drugs Lapatinib (Primary) ; Cisplatin; Gemcitabine
- Indications Urogenital cancer
- Focus Adverse reactions
- 01 Jan 2016 Status changed from active, no longer recruiting to completed, as per the results published in the Oncology
- 23 Apr 2012 Planned end date (Aug 2012) added as reported by ClinicalTrials.gov.
- 23 Apr 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.